The U.S. Patent and Trademark Office has issued Aperio a patent entitled, "Data Management in a Linear-array-based Microscope Slide Scanner."
The new xCELLigence RTCA HT Instrument from Roche merges the power and flexibility of xCELLigence System technology with high-throughput analyses and workflows for automated screening applications.
Cole-Parmer has redesigned and updated its line of Polystat circulating baths and immersion circulators, which offer temperature stability for a range of laboratory applications including Polystat Open Heating Circulating Baths and Polystat Stainless Steel Heating Circulating Baths.
The Stanford University School of Medicine and SanBio Inc. announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from previous stroke injuries.
AiCuris announced that AIC246, the company’s inhibitor against the human cytomegalovirus HCMV has been granted Orphan Drug designation for the prevention of HCMV disease.
Thermo Fisher Scientific Inc., announced the availability of a new Thermo Scientific Atlas Chromatography Data System (CDS) instrument control software for the Shimadzu Prominence and Prominence XR HPLC.
Phenomenex Inc. introduces the Solid Phase Extraction (SPE) Method Development Tool, an online resource that develops methods across a variety of sample matrices and compounds.
Chemical Abstracts Service introduced SciPlanner, an interactive workspace that enables scientists to more quickly identify synthesis options for designing the best research pathways and approaches.
Thermo Fisher Scientific Inc. introduced its Smart-Vue wireless monitoring solution. Smart-Vue protects precious samples by monitoring key laboratory parameters including temperature, CO2 concentration, humidity and differential pressure.
Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637.
Cumberland Pharmaceuticals Inc. said it acquired the rights to a molecule named ifetroban and will test it as a potential in-hospital treatment for a condition that involves progressive kidney failure.
Two new studies highlight the power of sequencing cancer patients' genomes as a diagnostic tool, helping doctors decide the best course of treatment and researchers identify new cancer susceptibility mutations that can be passed from parent to child.
NeuroVive Pharmaceutical and Hospices Civils de Lyon has dosed the first of 1,000 enrollees in its phase 3 trial of CicloMulsion for patients undergoing PCI for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue.
Anavex Life Sciences Corp. announced that the first healthy human volunteers have been initially dosed in its Phase 1 clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease.
Forest Laboratories Inc. said its net income jumped in the fiscal fourth quarter compared to last year, when it made a large payment to AstraZeneca PLC to get the rights to a potential antibacterial drug cocktail.